The North America Gabapentin Market would witness market growth of 3.8% CAGR during the forecast period (2022-2028).
Gabapentin is one of the two medications used in the PROMETA protocol of treatment for methamphetamine, cocaine, and alcohol addiction. When taken in a dosage of 1200 milligrams, reports indicate that gabapentin has the potential to minimize the severity of symptoms of withdrawal as well as cravings caused by stopping the intake or usage of methamphetamine. Also, it minimizes the symptoms of withdrawal and assists those who are addicted to the medicines that are prescribed.
In addition, gabapentin has recently been shown to be effective in treating various conditions related to the nervous system. In recent years, gabapentin has become one of the most consumed and prescribed drugs. The increasing use can be ascribed to elements like the rising prevalence of seizures and neuropathic pain, as well as the rising use of the medicine as a pain reliever. In addition, the growing elderly population, increased government activities, and pharmaceutical corporations' R&D spending are further motivators. Gabapentin is an anticonvulsant typically provided to people with epilepsy to control their seizure activity.
In North America, epilepsy care is hampered by the lack of quality, quantity, and availability of diagnostic tools, medications, specialists, resources, and facilities. There is little public knowledge of epilepsy, which is more prevalent than Parkinson's disease, multiple sclerosis, or autism. Consequently, in recent years, the regional governments have been putting more effort into raising awareness about epilepsy. Such efforts have resulted in greater attention to the care of epileptics, facilitating the ease of drug accessibility. Therefore, the growing demand for gabapentin to treat epilepsy will accelerate the market's growth in the coming years.
The US market dominated the North America Gabapentin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $719.8 million by 2028. The Canada market is poised to grow at a CAGR of 6.2% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 5.2% during (2022 - 2028).
Based on Application, the market is segmented into Epilepsy, Restless Legs Syndrome, Neuropathic Pain, and Others. Based on Dosage Form, the market is segmented into Capsule, Tablet and Oral Solution. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Gabapentin Market is Projected to reach USD 2.6 Billion by 2028, at a CAGR of 4.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Amneal Pharmaceuticals, Inc., Cipla Limited, and Apotex, Inc.
By Application
By Dosage Form
By Distribution Channel
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 